Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB25FJJSL
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,036
Award facts
- Contract value 100% obligated
- $15,036.07 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $15,036.07. The contract, awarded September 10, 2025, with an ultimate completion date of September 11, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026.
AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems. The SPE2DX contract represents a global pharmaceutical support vehicle enabling the company to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to customers including the Defense Health Agency and U.S. Coast Guard. Dupixent, a specialty biologic medication used for treating atopic dermatitis, moderate-to-severe asthma, and chronic rhinosinusitis with nasal polyps, falls within the company's extensive portfolio of brand-name pharmaceutical products delivered through the federal procurement system.
Quick answers
Who was awarded contract SPE2DB25FJJSL?
SPE2DB25FJJSL was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 10, 2025.
How much is contract SPE2DB25FJJSL worth?
The government has obligated $15,036 on SPE2DB25FJJSL.
Is contract SPE2DB25FJJSL an order under another contract?
Yes. SPE2DB25FJJSL is a delivery order under SPE2DB24D2102, an indefinite delivery contract.
Was contract SPE2DB25FJJSL competed?
The extent of competition for SPE2DB25FJJSL was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award